ANIP News and Press, ANI Pharmaceuticals Inc. From 05/07/21

-- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 -- -- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 -- -- Cortrophin ® G...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, S...

ANI Pharmaceuticals (ANIP) has acquired the new drug applications (NDAs) for Oxistat Lotion, Veregen Ointment, and Pandel Cream and the abbreviated new drug application for ApexiCon E Cream from Sandoz Inc.Pandel Cream will be transitioned later upon receiving the requisite app...

-- Accretive transaction in line with growth strategy laid out for Branded Products business -- ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (“NDAs”) for OXISTAT ® Lotion, VERE...

ANI Pharmaceuticals, Inc. (ANIP) Q4 2020 Earnings Conference Call March 9, 2021 08:30 ET Company Participants Lisa Wilson - In-Site Communications, Investor Relations Nikhil Lalwani - President & Chief Executive Officer Stephen Carey - Chief Financial Officer Conference Call Participants ...

ANI Pharmaceuticals ([[ANIP]] -1.4%) has agreed to acquire privately-held Novitium Pharma for a total consideration of $163.5M in cash and equity.The transaction is expected to close in H2 2021, subject to regulatory approvals and approval by ANI shareholders.The purchase price incl...

Image source: The Motley Fool. ANI Pharmaceuticals Inc (NASDAQ: ANIP) Q4 2020 Earnings Call Mar 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ANI Pharmaceuticals Inc (ANIP) Q4 2020 Earnings Call Transcript

ANI Pharmaceuticals (ANIP): Q4 Non-GAAP EPS of $0.80 misses by $0.14; GAAP EPS of -$0.30 misses by $0.47.Revenue of $57.3M (+19.4% Y/Y) beats by $3.03M.Press Release For further details see: ANI Pharmaceuticals EPS misses by $0.14, beats on revenue

-- Fourth quarter 2020 net revenues of $57.3 million; net loss of $3.6 million and diluted loss per share of $0.30 -- -- Fourth quarter adjusted non-GAAP EBITDA of $17.2 million and adjusted non-GAAP diluted eps of $0.80 -- -- ANI defines strategy for sustainable futur...

Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 Expands Brand Portfolio with Addition of 505(b)(2) Pipeline and Enhances Scale of CDMO Business Purchase Price of $163.5 Million, including $89.5 Million in Cash and $74 Millio...